Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01712139 · ClinicalTrials.gov registry record · NA
Crossover Bioequivalence Study of Irbesartan HCTZ 300/25 mg Tablets Under Fasted Conditions
A NA study, sponsored by Roxane Laboratories.
- Completed
- Registry status
- NA
- Development phase
- 37
- Enrollment target
NCT01712139 is a NA study that has completed, run by Roxane Laboratories. The registered enrollment target is 37 participants.
The verdict
NCT01712139, a NA study, has completed, sponsored by Roxane Laboratories.
- COMPLETED
- Registry status
- NA
- Development phase
- 37 participants
- Enrollment target
Study Summary
The objective of this study was to prove the bioequivalence of Roxane Laboratories' Irbesartan and Hydrochlorothiazide 300 mg / 25 mg Tablets under fasted conditions.
Interventions
- DRUG Irbesartan and Hydrochlorothiazide
- DRUG Avalide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2007-09 |
| Est. Completion | 2007-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01712139
The ClinicalTrials.gov registry entry for NCT01712139 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roxane Laboratories, which has 93 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Irbesartan and Hydrochlorothiazide is the first listed.
NCT01712139 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01712139 about?
NCT01712139 is a clinical study titled "Crossover Bioequivalence Study of Irbesartan HCTZ 300/25 mg Tablets Under Fasted Conditions". The objective of this study was to prove the bioequivalence of Roxane Laboratories' Irbesartan and Hydrochlorothiazide 300 mg / 25 mg Tablets under fasted conditions.
What is the current status of trial NCT01712139?
This trial is currently completed. It is a NA study. The enrollment target is 37 participants. The study started on 2007-09. Estimated completion is 2007-09.
What interventions are being tested in trial NCT01712139?
The interventions under investigation include: Irbesartan and Hydrochlorothiazide (DRUG), Avalide (DRUG).
Who is sponsoring clinical trial NCT01712139?
This trial is sponsored by Roxane Laboratories, which has 93 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.